Pipeline

CDR-Life’s pipeline includes several wholly owned first-in-class immunotherapies against hematological and solid tumor malignancies. In addition, it includes a partnered retinal disease therapy program.

Oncology

Immunotherapies have been very successful in the treatment of certain cancers. However, efficacy and safety of immunotherapies currently on the market and in development are compromised by the following:

1. Lack of tumor selectivity causes significant off-tumor effects.
2. Lack of natural T cell-specific tumor antigens reduces efficacy of immune checkpoint inhibitors.
3. Loss of tumor antigen’s causes to tumor escape.

CDR-Life has a powerful antibody platform including several proprietary technologies for developing tumor-targeted immunotherapies that tackle these issues in both hematological and solid tumor malignancies.

Increasing tumor selectivity

Our LocATE (Local Activator and T cell Engager) antibodies redirect T cells AND co-inhibit the immune checkpoint locally in the cytolytic synapse. In vitro, in vivo, patient-derived ex vivo studies have shown superiority to bispecific T cell engagers as well as checkpoint inhibitor combination therapies.

This new mode of action (MoA) based on a trispecific antibody format tackles known relapse drivers in multiple myeloma by enabling co-inhibition of PD-L1. This is likely to block the tumor escape that leads to relapses in this currently incurable disease.

Re-directing T cells to oncogenic antigens

CDR-Life is generating T cell engaging antibodies against intracellular antigens to access highly tumor-specific oncogenes. This enables re-redirection of T cells specifically to tumor cells and can be combined with immune checkpoint inhibitors for increasing T cell activity.

A variety of solid tumor cancers have low mutational burden and poor response to immune checkpoint inhibitors. These novel T cell engagers hold great promise of increased efficacy in indications with poor checkpoint inhibitor responses.

Targeting multiple tumor antigens

CDR-Life’s platform for developing trispecific antibody therapies enables the development of T cell engagers that target two different tumor antigens. Such molecules are less vulnerable to tumor resistance development through antigen loss and are likely to increase response duration in cancers prone to antigen changes.